Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 all comers meta-analysis

sarimulab phase 2 low dose unpublished
 
NCT04315298
RCTsarilumab low dose (200mg)placeboCOVID 19 all comershigh
136/77 suggested
  • suggested 72 % decrease in ventilation but with a low degree of certainty due to high risk of bias
there were negative trends for most outcomes in the “severe” group, while there were positive trends for all outcomes in the “critical” group

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).